Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST) - PubMed
5 hours ago
- #metastatic colorectal cancer
- #randomized trial
- #ramucirumab
- A randomized phase II study (WJOG9216G/RECAST) compared FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for untreated metastatic colorectal cancer.
- Primary endpoint objective response rate (ORR) was similar between arms (59.3% vs 60.3%), with no significant difference.
- Progression-free survival (PFS) was comparable (median 11.5 vs 10.5 months), but early tumor shrinkage (ETS) and overall survival (OS) were significantly better in the FOLFIRI plus ramucirumab arm.
- FOLFOXIRI plus ramucirumab showed higher rates of grade ≥3 adverse events, including neutropenia, anorexia, and febrile neutropenia.
- First-line FOLFIRI plus ramucirumab demonstrated efficacy and safety comparable to doublet chemotherapy plus bevacizumab, while FOLFOXIRI plus ramucirumab was not superior.